COMMUNIQUÉS West-GlobeNewswire

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

18/09/2024 - 14:00

Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology [...]

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

18/09/2024 - 14:00

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual Meeting EFTISARC-NEO is the first trial to evaluate efti in a [...]

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

18/09/2024 - 14:00

MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by Myriad SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and [...]

Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)

18/09/2024 - 14:00

Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with clinical measures of liver disease SOUTH SAN FRANCISCO, Calif [...]

Merus annonce l'acceptation du résumé pour présentation lors du congrès de l’ESMO Asie 2024

18/09/2024 - 13:55

Les données cliniques intermédiaires relatives au pétosemtamab dans le traitement de deuxième intention ou ultérieur (2L+) du carcinome épidermoïde de la tête et du cou (CETC) ont été sélectionnées pour une présentation [...]

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

18/09/2024 - 13:50

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatments Expanded access policy will provide potential lifesaving Bria-IMT™ to those cancer patients in [...]

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

18/09/2024 - 13:30

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends [...]

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

18/09/2024 - 13:15

Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can successfully [...]

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO

18/09/2024 - 13:00

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today [...]

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

18/09/2024 - 13:00

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now approved to reduce [...]

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

18/09/2024 - 13:00

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years [...]

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

18/09/2024 - 13:00

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Engrail [...]

Tilray Medical Launches Redecan Cannabis Brand in Australia

18/09/2024 - 13:00

EU-GMP Certified Redecan Cannabis Now Available in Australia with Medical Prescription NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and [...]

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

18/09/2024 - 13:00

TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

18/09/2024 - 13:00

- Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action date of November 28, 2024 [...]

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

18/09/2024 - 12:15

Clearance to proceed also received from health authorities in South Korea and Australia, with Taiwan expected in 4Q 2024 First U.S. patient randomized DANBURY, Conn., Sept. 18, 2024 (GLOBE NEWSWIRE) -- MannKind [...]

KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare

18/09/2024 - 12:00

RIYADH, Saudi Arabia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has successfully concluded its participation at the 2024 NYC C3 Summit Davos of Healthcare, [...]

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

18/09/2024 - 12:00

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE [...]

ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment

18/09/2024 - 11:00

ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment ICT01, a humanized anti- [...]